428 related articles for article (PubMed ID: 22150116)
1. Denosumab and the current status of bone-modifying drugs in breast cancer.
Lee BL; Higgins MJ; Goss PE
Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
4. Bone-modifying agents as adjuvant therapy for early-stage breast cancer.
Figueroa-Magalhães MC; Miller RS
Oncology (Williston Park); 2012 Oct; 26(10):955-62. PubMed ID: 23176008
[TBL] [Abstract][Full Text] [Related]
5. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
[TBL] [Abstract][Full Text] [Related]
9. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
10. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
[TBL] [Abstract][Full Text] [Related]
11. Antiresorptive therapies in oncology and their effects on cancer progression.
Bundred N
Cancer Treat Rev; 2012 Oct; 38(6):776-86. PubMed ID: 22370427
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
13. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
14. Effects of bone-targeted agents on cancer progression and mortality.
Coleman R; Gnant M; Morgan G; Clezardin P
J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
[TBL] [Abstract][Full Text] [Related]
15. Denosumab an option for patients with bone metastasis from breast cancer.
Barton MK
CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
[No Abstract] [Full Text] [Related]
16. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Gnant M
Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
[TBL] [Abstract][Full Text] [Related]
18. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
19. Update on the pharmacological prevention of skeletal-related events in cancer patients.
Kennedy K; Patel H
Orthopedics; 2011 Dec; 34(12):982-5. PubMed ID: 22147215
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy of bone metastases in breast cancer patients.
Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
